Objective: To determine if dehydroepiandrosterone (DHEA) is beneficial in severe systemic lupus erythematosus (SLE).
Methods: A double-blinded, placebo-controlled, randomized clinical trial in 21 patients with severe and active SLE, manifestated primarily by nephritis, serositis or hematological abnormalities. In addition to conventional treatment with corticosteroids +/-immunosuppressives, patients received DHEA 200 mg/d vs placebo for 6 months, followed by a 6-month open label period. The primary outcome was a prospectively defined responder analysis, based on a quantitatively specified improvement of the principal severe lupus manifestation at 6 months.
Results: Nineteen patients were available for evaluation at 6 months. Baseline imbalance between the groups was noted, with the DHEA group having greater disease activity at baseline (P < 0.05 by physician's global assessment). Eleven patients were responders: 7/9 patients on DHEA vs 4=10 patients on placebo (P < 0.10). Of the secondary outcomes, mean improvement in SLE disease activity index (SLE-DAI) score was greater in the DHEA group (710.3 3.1 vs 73.9 1.4, P < 0.07). Bone mineral density at the lumbo-sacral spine showed significant reduction in the placebo group, but was maintained in the DHEA group.
Conclusion: DHEA therapy, when added to conventional treatment for severe SLE, may at most have a small added benefit with respect to lupus outcomes, but baseline imbalances in the study population limit the generalizability of the results. DHEA appears to have a protective effect with respect to corticosteroid-induced osteopenia in such patients.
Parker LN . Control of adrenal androgen secretion . Endocrin Metab Clin N Am1991; 20: 401–421 .
2.
Ebeling P , Koivisto VA . Physiological importance of dehydroepiandrosterone . Lancet1994; 343: 1479–1481 .
3.
Daynes RA , Araneo BA . Natural regulators of T-cell lymphokine production in vivo . J Immunother1992; 12: 174–179 .
4.
Daynes RA , Dudley DJ , Araneo BA . Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells . Eur J Immunol1990; 20: 793–802 .
5.
Daynes RA , Araneo BA , Dowell TA et al. Regulation of murine lymphokine production in vivo III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function . J Exp Med1990; 171: 979–996 .
6.
Suzuki T , Suzuki N , Daynes RA et al. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells . Clin Immunol Immunopathol1991; 61: 202–210 .
7.
van Vollenhoven RF , McGuire JL . Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases?Cleveland Clinic J of Med1994; 61: 276–284 .
8.
van Vollenhoven RF , Engleman EG , McGuire JL . Dehydroepiandrosterone (DHEA) in systemic lupus erythematosus: results of a doubleblinded, placebo-controlled, randomized clinical trial . Arthritis Rheum1995; 38: 1826–1831 .
9.
Liang MH , Socher SA , Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum1989; 32: 1107–1118 .
10.
Bombardier C , Gladman DD , Urowitz MB et al. Derivation of the SLEDAI: a Disease Activity Index for lupus patients . Arthritis Rheum1992; 35: 630–640 .
11.
Jungers P , Nahoul K , Pelissier C et al. Low plasma androgens in women with active or quiescent systemic lupus erythematosus . Arthritis Rheum1982; 25: 454–462 .
12.
Lahita RG , Bradlow HL , Ginzler E et al. Low plasma androgens in women with systemic lupus erythematosus . Arthritis Rheum1987; 30: 241–248 .
13.
Roubinian JR , Talal N , Siiteri PK et al. Sex hormone modulation of autoimmunity in NZB/NZW mice . Arthritis Rheum1979; 22: 1162–1169 .
14.
Roubinian JR , Talal N , Greenspan JS et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice . J Exp Med1987; 147: 1568–1583 .
15.
Melez KA , Boegel WA , Steinberg AD . Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1females of different ages . Arthritis Rheum1980; 23: 41–48 .
16.
Lucas JA , Ahmed AA , Casey ML et al. Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice fed dehydroisoandrosterone . J Clin Invest1985; 75: 2091–2093 .
17.
Mastunaga A , Miller BC , Cottam GL . Dehydroisondrosterone prevention of autoimmune disease in NZB/W F1 mice: lack of an effect on associated immunological abnormalities . Biochimica et Biophysica Acta1989; 992: 265–271 .
18.
van Vollenhoven RF , McDevitt HO . Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone . Arthritis Rheum1992; 35: (Suppl) S207-S207 .
19.
Lahita RG , Cheng CY , Monder C et al. Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women . J Rheumatol1992; 19: 447–455 .
20.
Alcocer-Varela J , Alarcon-Segovia D . Decreased production of and response to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus . J Clin Invest1982; 69: 1388–1398 .
21.
Linker-Israeli M , Bakke AC , Kitridou RC et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE) . J Immunol1983; 130: 2651–2655 .
22.
Suzuki T , Suzuki N , Engleman EG et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE) . Clin and Exper Immunol1995; 99: 251–255 .
23.
van Vollenhoven RF , Morabito LM , Engleman EG et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months . J Rheumatol1998; 25: 285-289 .
24.
Hodgson SF . Corticosteroid-induced osteoporosis . Endocrinol Metabol Clin North Am1990; 19: 95–111 .
25.
Labrie F , Diamond P , Cusan L et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women . J Clin Endocrinol Metab1997; 82: 3498–3505 .
